Nurix Therapeutics, Inc. (NASDAQ: NRIX ) leads in targeted protein modulation with its proprietary DELigase platform. This way, it develops therapies for cancer and inflammatory conditions. NRIX offers solutions for challenging conditions resistant to conventional treatments, using the natural processesMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohio U ...

SAN FRANCISCO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, will present a corporate update at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 3:00 p.m. PT, in San Francisco. The event will be we ...

Company Overview - Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing targeted protein modulation drugs for cancer and inflammatory diseases [8] - The company utilizes an integrated discovery platform called DELigase to identify and advance novel drug candidates targeting E3 ligases [8] Product Development - The FDA has granted Fast Track designation for NX-5948, a selective degrader of Bruton’s tyrosine kinase (BTK), for treating adult patients with relapsed or refractory Waldenstrom’s macroglobulinemia after at least two lines of therapy [1][2] - NX-5948 has previously received Fast Track designation for chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) and has also been granted PRIME designation by the European Medicines Agency (EMA) for the same indications [2] Clinical Trials - Encouraging safety and efficacy data from the ongoing Phase 1 clinical trial of NX-5948 have been reported, showing early promise for clinical benefit and potential for durable outcomes [2] - The company continues to enroll patients in the Phase 1b expansion cohort and plans to share additional clinical data in 2025 [2] Market Context - Waldenstrom’s macroglobulinemia is a rare type of non-Hodgkin’s lymphoma with an incidence of approximately 1,200 to 1,900 cases annually in the U.S. [3] - There are currently no approved therapies for treating WM patients after BTK inhibitor therapy, highlighting the unmet medical need that NX-5948 aims to address [3]

Core Insights - Nurix Therapeutics has received Fast Track designation from the FDA for NX-5948, a selective BTK degrader, aimed at treating adult patients with relapsed or refractory Waldenstrom's macroglobulinemia after at least two lines of therapy, including a BTK inhibitor [1][2] - The Fast Track designation highlights the unmet medical need in Waldenstrom's macroglobulinemia, especially for patients whose cancer has progressed after BTK inhibitor therapy [2] - NX-5948 has also received Fast Track designation for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and PRIME designation from the EMA for the same indication [2] Company Overview - Nurix Therapeutics is a clinical stage biopharmaceutical company focused on developing targeted protein modulation drugs for cancer and inflammatory diseases [8] - The company utilizes an integrated discovery platform called DELigase to identify and advance novel drug candidates targeting E3 ligases, which modulate protein levels within cells [8] - NX-5948 is currently in a Phase 1 clinical trial for relapsed or refractory B cell malignancies, demonstrating potency against tumor cell lines resistant to existing BTK inhibitors [6][8] Disease Context - Waldenstrom's macroglobulinemia is a rare type of non-Hodgkin's lymphoma with an incidence of approximately 0.36 to 0.57 per 100,000 people in the U.S., translating to about 1,200 to 1,900 new cases annually [3] - The disease is characterized by the production of monoclonal IgM, leading to anemia, bleeding, and impaired immune function, with no approved therapies for patients after BTK inhibitor treatment [3] Regulatory Designations - The FDA's Fast Track designation aims to expedite the development and review of drugs addressing serious conditions and unmet medical needs, allowing for more frequent interactions with the FDA [4] - The EMA's PRIME initiative provides early and enhanced support to developers of promising medicines, facilitating faster patient access [5]

SAN FRANCISCO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, will present a corporate update at the Piper Sandler 36th Annual Healthcare Conference, at 2:30 p.m. ET on Tuesday, December 3, 2024, in New York City. The event will be ...

The PRIME initiative provides enhanced support to developers of promising medicines to optimize development plans and accelerate evaluation Pivotal trials of NX-5948 are planned to initiate in 2025 SAN FRANCISCO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that the European Medicines Agency (EMA) has granted P ...

NX-5948 demonstrated robust clinical activity with objective responses observed in 7 of 9 (77.8%) evaluable Waldenstrom's patients in the ongoing Phase 1a/1b clinical trial Responses are durable and deepen over time with two patients on treatment for greater than one year Data were presented at the 12th International Workshop on Waldenstrom's Macroglobulinemia (IWWM-12) SAN FRANCISCO, Oct. 19, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company develo ...

• damage to relationships with any potential collaborators; • injunctions or the imposition of civil or criminal penalties; or 71 Table of Contents Table of Contents Table of Contents Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving ...

[Nurix logo] Exhibit 99.1 Nurix Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Provides a Corporate Update Presented positive clinical data at the European Hematology Association Congress supporting a potential best-in-class profile for NX- 5948 for the treatment of CLL Strengthened leadership with appointment of Paula G. O'Connor, M.D., as chief medical of icer and Pasit Phiasivongsa, Ph.D., as chief technical of icer Strengthened financial position ending the quarter with cash and m ...

SAN FRANCISCO, July 11, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today reported financial results for the second quarter ended May 31, 2024, and provided a corporate update. Strengthened leadership with appointment of Paula G. O'Connor, M.D., as chief medical officer and Pasit Phiasivongsa, Ph.D., as chief technical officer "Our se ...